China NT Pharma Group Company Limited (HKG:1011)
Hong Kong
· Delayed Price · Currency is HKD 0.670
+0.020 (3.08%)
Apr 29, 2026, 3:38 PM HKT
HKG:1011 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 24.16 | 37.96 | 7.37 | - | 226.7 | Upgrade
|
| Revenue Growth (YoY) | -36.36% | 415.34% | - | - | 2.24% | Upgrade
|
| Cost of Revenue | 14.55 | 32.7 | - | - | 81.24 | Upgrade
|
| Gross Profit | 9.61 | 5.26 | 7.37 | - | 145.46 | Upgrade
|
| Selling, General & Admin | 21.97 | 18.49 | 63.57 | 22.62 | 229.19 | Upgrade
|
| Operating Expenses | 21.97 | 18.49 | 63.57 | 26.54 | 238.93 | Upgrade
|
| Operating Income | -12.36 | -13.23 | -56.21 | -26.54 | -93.47 | Upgrade
|
| Interest Expense | -27.84 | -31.54 | -28.82 | -39.37 | -88.73 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.04 | 0.24 | Upgrade
|
| Earnings From Equity Investments | - | 10.24 | 37.04 | 9 | 34.49 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 6.66 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | -6.06 | 0.26 | 0.5 | 6.5 | Upgrade
|
| EBT Excluding Unusual Items | -40.19 | -40.58 | -47.71 | -56.37 | -134.32 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -1.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.08 | -5.92 | - | -0.63 | -6.04 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -7.01 | 12.29 | - | 41.04 | Upgrade
|
| Legal Settlements | - | - | - | - | -40.63 | Upgrade
|
| Other Unusual Items | -0.14 | 0.03 | 2.05 | 6.95 | -7.4 | Upgrade
|
| Pretax Income | -26.26 | -53.48 | -33.37 | -50.04 | -148.75 | Upgrade
|
| Income Tax Expense | - | -0.12 | 0.12 | - | 2.58 | Upgrade
|
| Earnings From Continuing Operations | -26.26 | -53.36 | -33.49 | -50.04 | -151.33 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -110.1 | -16.37 | - | Upgrade
|
| Net Income to Company | -26.26 | -53.36 | -143.59 | -66.41 | -151.33 | Upgrade
|
| Minority Interest in Earnings | 0.21 | - | - | - | 1.8 | Upgrade
|
| Net Income | -26.04 | -53.36 | -143.59 | -66.41 | -149.54 | Upgrade
|
| Net Income to Common | -26.04 | -53.36 | -143.59 | -66.41 | -149.54 | Upgrade
|
| Shares Outstanding (Basic) | 617 | 264 | 239 | 190 | 189 | Upgrade
|
| Shares Outstanding (Diluted) | 617 | 264 | 239 | 190 | 189 | Upgrade
|
| Shares Change (YoY) | 133.61% | 10.72% | 25.59% | 0.51% | 0.14% | Upgrade
|
| EPS (Basic) | -0.04 | -0.20 | -0.60 | -0.35 | -0.79 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.20 | -0.60 | -0.35 | -0.79 | Upgrade
|
| Free Cash Flow | - | -9.24 | 39.74 | 31.72 | -135.98 | Upgrade
|
| Free Cash Flow Per Share | - | -0.04 | 0.17 | 0.17 | -0.72 | Upgrade
|
| Gross Margin | 39.78% | 13.86% | 100.00% | - | 64.16% | Upgrade
|
| Operating Margin | -51.18% | -34.84% | -763.07% | - | -41.23% | Upgrade
|
| Profit Margin | -107.80% | -140.56% | -1949.36% | - | -65.96% | Upgrade
|
| Free Cash Flow Margin | - | -24.35% | 539.55% | - | -59.98% | Upgrade
|
| EBITDA | -12.32 | -13.18 | -51.63 | -9.39 | -57.27 | Upgrade
|
| EBITDA Margin | -50.98% | -34.72% | - | - | -25.26% | Upgrade
|
| D&A For EBITDA | 0.05 | 0.05 | 4.58 | 17.16 | 36.2 | Upgrade
|
| EBIT | -12.36 | -13.23 | -56.21 | -26.54 | -93.47 | Upgrade
|
| EBIT Margin | -51.18% | -34.84% | - | - | -41.23% | Upgrade
|
| Advertising Expenses | - | - | - | - | 141.48 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.